IL154991A0 - Immunogen comprising ligand bound hiv envelope protein - Google Patents

Immunogen comprising ligand bound hiv envelope protein

Info

Publication number
IL154991A0
IL154991A0 IL15499101A IL15499101A IL154991A0 IL 154991 A0 IL154991 A0 IL 154991A0 IL 15499101 A IL15499101 A IL 15499101A IL 15499101 A IL15499101 A IL 15499101A IL 154991 A0 IL154991 A0 IL 154991A0
Authority
IL
Israel
Prior art keywords
immunogen
envelope protein
ligand bound
hiv envelope
bound hiv
Prior art date
Application number
IL15499101A
Other languages
English (en)
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IL154991A0 publication Critical patent/IL154991A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15499101A 2000-09-22 2001-09-24 Immunogen comprising ligand bound hiv envelope protein IL154991A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23432700P 2000-09-22 2000-09-22
US28517301P 2001-04-23 2001-04-23
US32370201P 2001-09-21 2001-09-21
US32369701P 2001-09-21 2001-09-21
PCT/US2001/029830 WO2002024149A2 (en) 2000-09-22 2001-09-24 Immunogen comprising ligand bound hiv envelpe protein

Publications (1)

Publication Number Publication Date
IL154991A0 true IL154991A0 (en) 2003-10-31

Family

ID=27499729

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15499101A IL154991A0 (en) 2000-09-22 2001-09-24 Immunogen comprising ligand bound hiv envelope protein

Country Status (11)

Country Link
US (2) US7101552B2 (xx)
EP (1) EP1331942A4 (xx)
JP (1) JP2004511444A (xx)
KR (1) KR20030036819A (xx)
CN (1) CN1505528A (xx)
AU (2) AU9466701A (xx)
BR (1) BR0114094A (xx)
CA (1) CA2423127A1 (xx)
IL (1) IL154991A0 (xx)
MX (1) MXPA03002480A (xx)
WO (1) WO2002024149A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307130A4 (en) 2000-02-04 2005-01-12 Beth Israel Hospital VACCINE AGAINST HUMAN IMMUNE WEAK VIRUS
US20080213296A1 (en) * 2000-09-22 2008-09-04 Duke University Immunogen
US7033593B2 (en) * 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
KR20030036819A (ko) 2000-09-22 2003-05-09 듀크 유니버시티 면역원
EP1450857B1 (en) * 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US7195768B2 (en) * 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
EP1461077A4 (en) 2001-11-07 2006-01-25 Univ Duke POLYVALENT IMMUNOGEN
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US20060014148A1 (en) 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
US7074238B2 (en) 2003-07-08 2006-07-11 Archus Orthopedics, Inc. Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces
WO2005028625A2 (en) 2003-09-17 2005-03-31 Duke University Consensus/ancestral immunogens
US20050249428A1 (en) * 2004-05-07 2005-11-10 Ming-Jun Chen Method of weeding out repeating patterns from programs
US8398681B2 (en) 2004-08-18 2013-03-19 Gmedelaware 2 Llc Adjacent level facet arthroplasty devices, spine stabilization systems, and methods
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
WO2006050219A2 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5516632A (en) 1988-02-08 1996-05-14 Duke University Synthetic peptides
US5217473A (en) * 1989-12-05 1993-06-08 Inbae Yoon Multi-functional instruments and stretchable ligating and occluding devices
EP0652764B1 (en) 1992-02-10 2000-05-24 Duke University Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens
CA2152915A1 (en) * 1992-12-31 1994-07-21 Jonathan M. Gershoni Antibodies directed against binding-associated epitopes
PT699077E (pt) 1993-05-07 2002-04-29 Bio Merieux Inc Complexo imunogenico de hiv
EP0762895B1 (en) 1994-04-29 2002-08-07 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
AU7465696A (en) 1995-10-20 1997-05-07 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
WO2000008043A2 (en) * 1998-08-03 2000-02-17 The University Of Montana Prevention and treatment of viral disease
EP1307130A4 (en) 2000-02-04 2005-01-12 Beth Israel Hospital VACCINE AGAINST HUMAN IMMUNE WEAK VIRUS
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
KR20030036819A (ko) * 2000-09-22 2003-05-09 듀크 유니버시티 면역원
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
EP1461077A4 (en) 2001-11-07 2006-01-25 Univ Duke POLYVALENT IMMUNOGEN
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
WO2003046137A2 (en) 2001-11-27 2003-06-05 Duke University Hiv envelope v3-ccr5 binding site immunogen
US20060014148A1 (en) 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
CA2526339A1 (en) 2003-05-19 2005-02-24 Duke University Polyvalent immunogen
WO2005028625A2 (en) 2003-09-17 2005-03-31 Duke University Consensus/ancestral immunogens

Also Published As

Publication number Publication date
US7070787B2 (en) 2006-07-04
WO2002024149A2 (en) 2002-03-28
MXPA03002480A (es) 2004-05-24
KR20030036819A (ko) 2003-05-09
BR0114094A (pt) 2003-07-22
WO2002024149A3 (en) 2002-09-06
CN1505528A (zh) 2004-06-16
EP1331942A2 (en) 2003-08-06
US20040039172A1 (en) 2004-02-26
US7101552B2 (en) 2006-09-05
AU2001294667B2 (en) 2006-08-17
AU9466701A (en) 2002-04-02
EP1331942A4 (en) 2005-03-16
US20020086283A1 (en) 2002-07-04
CA2423127A1 (en) 2002-03-28
JP2004511444A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
IL154991A0 (en) Immunogen comprising ligand bound hiv envelope protein
EP1329217A4 (en) SOLID PREPARATIONS
HUP0302636A3 (en) Split enveloped virus preparation
GB2363221B (en) Summary creation
GB0020050D0 (en) Folder
IL153539A0 (en) Protein complexes and methods for the preparation thereof
EP1337440A4 (en) DOCUMENT ENVELOPE
GB0012054D0 (en) Ligands
AU2002365576A8 (en) Hiv envelope v3-ccr5 binding site immunogen
GB0027905D0 (en) New protein
AU8252101A (en) Oct preparations
AU2001274676A1 (en) Plant-signalling ligand like proteins
GB0009181D0 (en) Protein
GB0025677D0 (en) New protein
EP1179592A4 (en) NECTIN-3 PROTEINS
EP1323734A4 (en) BINDING PROTEIN TO IRAP
GB9929923D0 (en) Antigen preparations
PL337742A1 (en) Envelope
GB0014842D0 (en) Biocidal proteins
GB0027308D0 (en) Drug-activated proteins
GB0008774D0 (en) Protein
GB0030294D0 (en) Protein
GB0031341D0 (en) Protein
GB0003039D0 (en) Improved file
TW493600U (en) Environment-protectioned envelope allowing repetitive uses